SCHEMBL2306502

SCHEMBL2306502

O[C@@H](CCl)c1ccc(Cl)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AOC3 Q16853 1/20 0.53
LMNA P02545 3/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
TSHR P16473 3/20 0.42
MAPK1 P28482 2/20 0.42
HIF1A Q16665 2/20 0.42
TDP1 Q9NUW8 2/20 0.42
ALOX15 P16050 1/20 0.41
APEX1 P27695 1/20 0.41
GABBR2 O75899 1/20 0.41
GABBR1 Q9UBS5 1/20 0.41
GAA P10253 1/20 0.41
TP53 P04637 1/20 0.41
HPGD P15428 1/20 0.41
ADRB2 P07550 1/20 0.41
CYP2A6 P11509 1/20 0.40
IDO1 P14902 2/20 0.39
HSD17B10 Q99714 1/20 0.39
BRD4 O60885 1/20 0.39
HDAC4 P56524 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3924286 1.00 AOC3 (0.53) AOC3LMNASMN1; SMN2TSHRMAPK1
SCHEMBL3924289 1.00 AOC3 (0.53) AOC3LMNASMN1; SMN2TSHRMAPK1
SCHEMBL29700206 0.82 AOC3 (0.55) AOC3LMNASMN1; SMN2TSHRMAPK1
SCHEMBL10799093 0.82 TAAR1 (0.39) AOC3LMNASMN1; SMN2TSHRHIF1A
SCHEMBL3917589 0.81 AOC3 (0.50) AOC3LMNASMN1; SMN2TSHRMAPK1
SCHEMBL3917591 0.81 AOC3 (0.50) AOC3LMNASMN1; SMN2TSHRMAPK1
SCHEMBL27504475 0.80 TAAR1 (0.60) LMNASMN1; SMN2TSHRHIF1ATDP1
SCHEMBL6715483 0.80 TAAR1 (0.60) LMNASMN1; SMN2TSHRHIF1ATDP1
SCHEMBL1155443 0.80 AOC3 (0.53) AOC3LMNASMN1; SMN2TSHRMAPK1
SCHEMBL4297797 0.80 AOC3 (0.53) AOC3LMNASMN1; SMN2TSHRMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110016444-B Acinetobacter ZJPH1806 and application thereof in preparation of miconazole chiral intermediate 浙江工业大学 2021-05-11 CN claimed
EP-0718407-B1 Intermediates for the synthesis of eliprodil enantiomers and process for their preparation SANOFI SYNTHELABO (FR) 2002-02-13 EP claimed
US-5677168-A Enantiomeric separation of (RS)1-(4-chlorophenyl)-2-chloroethanol by lipase catalyzed hydrolysis of its acetate SYNTHELABO (FR) 1997-10-14 US claimed
EP-0718407-A1 Intermediates for the synthesis of eliprodil enantiomers and process for their preparation SYNTHELABO (FR) 1996-06-26 EP claimed
CN-119614529-A Short-chain dehydrogenase, engineering bacteria and application thereof in asymmetric reduction of potential chiral carbonyl compounds 杭州文德阶生物科技有限公司 2025-03-14 CN disclosed
CN-110016444-B Acinetobacter ZJPH1806 and application thereof in preparation of miconazole chiral intermediate 浙江工业大学 2021-05-11 CN disclosed
CN-110016444-B Acinetobacter ZJPH1806 and application thereof in preparation of miconazole chiral intermediate 浙江工业大学 2021-05-11 CN disclosed
EP-1741693-B1 PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE ALCOHOLS NAGOYA IND SCIENCE RES INST (JP) 2011-08-03 EP disclosed
US-20070225528-A1 Process for Producing Optically Active Alcohol NAGOYA INDUSTRIAL SCIENCE RESEARCH CENTER (JP) 2007-09-27 US disclosed
EP-1741693-A1 PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE ALCOHOLS Nagoya Industrial Science Research Institute (JP) 2007-01-10 EP disclosed
CN-1668753-A Coupled enzymatic reaction system using a formate dehydrogenase derived from candida boidinii DEGUSSA (DE) 2005-09-14 CN disclosed
CN-1668738-A Two-phase coupled enzymatic reaction system based on alcohol dehydrogenase DEGUSSA (DE) 2005-09-14 CN disclosed
EP-0718407-B1 Intermediates for the synthesis of eliprodil enantiomers and process for their preparation SANOFI SYNTHELABO (FR) 2002-02-13 EP disclosed
US-5677168-A Enantiomeric separation of (RS)1-(4-chlorophenyl)-2-chloroethanol by lipase catalyzed hydrolysis of its acetate SYNTHELABO (FR) 1997-10-14 US disclosed
US-5677168-A Enantiomeric separation of (RS)1-(4-chlorophenyl)-2-chloroethanol by lipase catalyzed hydrolysis of its acetate SYNTHELABO (FR) 1997-10-14 US disclosed
EP-0718407-A1 Intermediates for the synthesis of eliprodil enantiomers and process for their preparation SYNTHELABO (FR) 1996-06-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070225528-A1 Process for Producing Optically Active Alcohol ADH1C, ADH1A, ADH5 AOC3 2253/4885LMNA 3010/4885SMN1; SMN2 4638/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.